BBOT vs LEN · $610.4M cap vs rev $34.19B
BridgeBio Oncology Therapeutics, Inc. (BBOT) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.
LEN (LEN) common stock.
BBOT does not have a complete income-statement cache yet.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
BBOT currently screens at market cap $610.4M. LEN currently screens at market cap $0.
Not investment advice. Open the BBOT and LEN stock pages for the full models.
Not investment advice.